ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos12.38 M11.31 M10.34 M10.4 M14.03 M9.46 M44.23 MInvestigación y desarrollo43.78 M34.89 M29.58 M23.27 M24.48 M21.53 M98.85 MBeneficio operativo-33.39 M-16.83 M-11.62 M-16.51 M-31.31 M-28.93 M-88.36 MTotal de ingresos no operativos3.38 M2.75 M2.44 M3.06 M2.22 M34 K7.76 MGastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses171 K-21 K-127 K-170 K-2.09 M-1 000-2.39 MIngresos/gastos extraordinarios3.21 M2.77 M2.57 M3.23 M4.32 M35 K10.15 MBeneficio antes de impuestos-30.01 M-14.08 M-9.18 M-13.45 M-29.08 M-28.9 M-80.6 MParticipación en los beneficios0——————Impuestos-5 00004 0000-5 000——Participación minoritaria———————Otros ingresos/gastos después de impuestos0———0——Beneficio neto antes de actividades interrumpidas-30 M-14.08 M-9.18 M-13.45 M-29.08 M-26.96 M-78.67 MOperaciones suspendidas———————Beneficio neto-30 M-14.08 M-9.18 M-13.45 M-29.08 M-26.96 M-78.67 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-30 M-14.08 M-9.18 M-13.45 M-29.08 M-26.96 M-78.67 MBeneficio básico por acción-1.1-0.52-0.34-0.49-1.05-0.95-2.83Beneficio por acción diluido-1.1-0.52-0.34-0.49-1.05-0.95-2.83Número medio de acciones ordinarias27 M27.11 M27.13 M27.19 M27.39 M28.42 M—Acciones diluidas27 M27.11 M27.13 M27.19 M27.39 M28.42 M—EBITDA———————EBIT-33.39 M-16.83 M-11.62 M-16.51 M-31.31 M-28.93 M-88.36 MCosto de los ingresos———————Otros costes de producción———————Amortización y depreciación (flujo de caja)———————
Arcturus Therapeutics Holdings Inc. - Common Stock
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.